Drugs

, Volume 49, Supplement 2, pp 92–99 | Cite as

Fluoroquinolones in Paediatrics — 1995

  • Ron Dagan
State-Of-The-Art Presentations

Summary

The fluoroquinolones are characterised by a broad spectrum of antibacterial activity that includes many Mycobacterium, Chlamydia, Legionella, and Mycoplasma species as well as many multiply-resistant bacterial strains, good oral bioavailability, extensive tissue penetration, low protein binding and long elimination half-lives.

Numerous clinical trials have shown that these compounds are effective and well tolerated in the treatment of adult patients with various infections, including urinary tract, respiratory tract, skin and soft tissue, bone and joint, and gynaecological infections, sexually transmitted diseases, infectious diarrhoea, infections in immunocompromised patients, and in surgical prophylaxis. Thus, there is increasing pressure to use this class of drugs in paediatric patients. However, concerns regarding adverse effects, particularly cartilage toxicity, have restricted development of the fluoroquinolone compounds for use in this population. Potential indications include Pseudomonas infections (mainly exacerbations of cystic fibrosis), urinary tract, gastrointestinal and central nervous system infections, infections in immunocompromised patients, certain otorhinolaryngological infections and infections caused by multiply-resistant pathogens. To date, clinical experience gained with fluoroquinolones in paediatric infections, which has been mainly on a compassionate-use basis, indicates that well-designed formal studies should be conducted to fully assess the efficacy and tolerability of these agents in specific indications in children.

Keywords

Cystic Fibrosis Fluoroquinolones Norfloxacin Nalidixic Acid Typhoid Fever 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Von Rosenstiel N, Adam D. Quinolone antibacterials — an up-date of their pharmacology and therapeutic use. Drugs 1993; 47: 371–401Google Scholar
  2. 2.
    Schaad UB. Role of the new quinolones in pediatric practice. Pediatric Infect Dis J 1992; 11: 1043–6CrossRefGoogle Scholar
  3. 3.
    Schaad UB. Use of quinolones in paediatrics. Drugs 1993; 45 Suppl. 3: 37–41PubMedCrossRefGoogle Scholar
  4. 4.
    Chysky V, Kapila K, Hullmann R, et al. Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use. Emphasis on joint evaluation. Infection 1991; 19: 289–96Google Scholar
  5. 5.
    Kubin R. Safety and efficacy of ciprofloxacin in paediatric patients view. Infection 1993; 21: 413–21PubMedCrossRefGoogle Scholar
  6. 6.
    Norrby SR. Side-effects of quinolones: comparison between quinolones and other antibiotics. Eur J Clin Microbiol Infect Dis 1991; 10: 378–83PubMedCrossRefGoogle Scholar
  7. 7.
    Wolfson JS. Quinolone antimicrobial agents: adverse effects and bacterial resistance. Eur J Clin Microbiol Infect Dis 1989; 8: 1080–9PubMedCrossRefGoogle Scholar
  8. 8.
    Ingham B, Brentvall DW, Dale EA, et al. Arthropathy induced by antibacterial fused N-alkyl-4-pyridone-3-carboxylic acids. Toxicol Lett 1977; 1: 21–6CrossRefGoogle Scholar
  9. 9.
    Schmidt M, Hoffmann K. The use of quinolones in children —toxicological aspects. Adv Antimicrob Antineoplast Chemother 1992; 11: 251–5Google Scholar
  10. 10.
    Schlüter G. Ciprofloxacin: review of its potential toxicologic effects. Am J Med 1987; 82 Suppl. 4A: 91–3Google Scholar
  11. 11.
    Schaad UB, Wedgwood-Krucko J. Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity. Infection 1987; 15: 165–8PubMedCrossRefGoogle Scholar
  12. 12.
    Schaad UB. Toxicity of quinolones in pediatric patients. Adv Antimicrob Antineopl Chemother 1992; 11: 259–65Google Scholar
  13. 13.
    Greniel B. Évaluation de la toxicité des quinolones en pédiatrie. In: Aujard Y, Gendrel D, editors. Les quinolones en pédiatrie. Paris: Médicine-Sciences, Flammarion, 1994: 117–22Google Scholar
  14. 14.
    Job-Deslandre C. Toxicité articulaire des quinolones en pédiatrie. In: Aujard Y, Gendrel D, editors. Les quinolones en pédiatrie. Paris: Médicine-Sciences, Flammarion, 1994: 61–4Google Scholar
  15. 15.
    Pertuiset E, Lenoir G, Jehanne M, et al. Tolérance articulaire de 1a péfloxacine et de l’ofloxacine chez les enfants et adolescents atteints de mucoviscidose. Rev Rhum Mal Osteoartic 1989; 56: 735–40PubMedGoogle Scholar
  16. 16.
    Stahlmann R, Forster C, Van Siche D. Quinolones in children. Are concerns over arthropathy justified?. Drug Saf 1993; 9: 397–403Google Scholar
  17. 17.
    Black A, Redmond AOB, Steen HJ, et al. Tolerance and safety of ciprofloxacin in pediatric patients. J Antimicrob Chemother 1990; 26 Suppl. F: 25–9PubMedCrossRefGoogle Scholar
  18. 18.
    Dab I, Desmyttere S, Malfroot A. Repeated use of ciprofloxacin in a pediatric cystic fibrosis population. Adv Antimicrob Antineopl Chemother 1992; 11–2: 143–6Google Scholar
  19. 19.
    LeBel M. Fluoquinolones in the treatment of cystic fibrosis: a critical appraisal. Eur J Clin Microbiol Infect Dis 1991; 10: 316–24PubMedCrossRefGoogle Scholar
  20. 20.
    Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991; 338: 725–6PubMedCrossRefGoogle Scholar
  21. 21.
    Schaad UB. Use of quinolones in pediatrics. Eur J Clin Microbiol Infect Dis 1991; 10: 355–60PubMedCrossRefGoogle Scholar
  22. 22.
    Fujii R. The use of norfloxacin in children in Japan. Adv Antimicrob Antineopl Chemother 1992; 11-2: 219–30Google Scholar
  23. 23.
    Van Wijk JAE, de Jong TPVM, Van Gool JD, et al. Using quinolones in urinary tract infections in children. Adv Antimicrob Antineopl Chemother 1992; 11-2: 157–61Google Scholar
  24. 24.
    Cruciani M, Bassetti D. Norfloxacin in the prophylaxis of bacterial infections in neutropenic children. Adv Antimicrob Antineopl Chemother 1992; 11-2: 209–16Google Scholar
  25. 25.
    Bennish M. Quinolone therapy in childhood shigellosis: past experience and current dilemmas. Adv Antimicrob Antineopl Chemother 1992; 11-2: 191–201Google Scholar
  26. 26.
    Chatzipanagiotou S, Papvasiliou E, Malamou-Lada E. Isolation of Campylobacter jejuni strains resistant to nalidixic acid and fluoroquinolones from children with diarrhea in Athens, Greece. Eur J Clin Microbiol Infect Dis 1993; 12: 566–9PubMedCrossRefGoogle Scholar
  27. 27.
    Piddock LJ, Griggs DJ, Hall ML, et al. Ciprofloxacin resistance in clinical isolates of Salmonella typhimurium. Antimicrob Agents Chemother 1993; 37: 662–6PubMedCrossRefGoogle Scholar
  28. 28.
    Dagan R. The place of fluoroquinolones for shigellosis in pediatric patients in Israel. Adv Antimicrob Antineopl Chemother 1992; 11-2: 203–6Google Scholar
  29. 29.
    Salam MA, Bennish ML. Therapy for shigellosis. I. Randomized double-blind trial of nalidixic acid in childhood shigellosis. J Pediatr 1988; 113: 901–7Google Scholar
  30. 30.
    Lolekha SS, Vivulbandhitkit P, Poonyarit P. Response to antimicrobial therapy for shigellosis in Thailand. Rev Infect Dis 1991; 13 Suppl. 4: 342–6CrossRefGoogle Scholar
  31. 31.
    Bennish ML, Salam MA, Khan WA, et al. Treatment of shigellosis. III. Comparison of one- or two-dose ciprofloxacin with standard 5-day therapy. Ann Intern Med 1992; 117: 727–34PubMedGoogle Scholar
  32. 32.
    Guyon P, Cassel-Beraud AM, Rakotonirina G, et al. Short-term pefloxacin therapy in Madagascan children with shigellosis due to multiresistant organisms. Clin Infect Dis 1994; 19: 1172–73PubMedCrossRefGoogle Scholar
  33. 33.
    Green SDR, Mewa Ilunga F, et al. An open study of ciprofloxacin for the treatment of proven or suspected extraintestinal salmonellosis in African children: a preliminary report. Adv Antimicrob Antineopl Chemother 1992; 11-2: 181–7Google Scholar
  34. 34.
    Gendrel D, Raymond J, Legall MA, et al. Use of pefloxacin after failure of initial antibiotic treatment in children with severe salmonellosis. Eur J Clin Microbiol Infect Dis 1993; 12: 209–11PubMedCrossRefGoogle Scholar
  35. 35.
    Dutta P, Rasaily R, Saha MR, et al. Ciprofloxacin for treatment of severe typhoid fever in children. Antimicrob Agents Chemother 1993; 37: 1197–9PubMedCrossRefGoogle Scholar
  36. 36.
    Bavdekar A, Chavdhari M, Bhave S, et al. Ciprofloxacin in typhoid fever. Indian J Pediatr 1991; 58: 335–9PubMedCrossRefGoogle Scholar
  37. 37.
    Raymond J, Moulin F, Badoual J, et al. Eradication of convalescent Salmonella carriage in children with two oral doses of pefloxacin. Eur J Clin Microbiol Infect Dis 1994; 13: 307–10PubMedCrossRefGoogle Scholar
  38. 38.
    Cohen R, Danan C, Aufrant C, et al. Fluoroquinolones et meningitis. In: Aujard Y, Gendrel D, editors. Les quinolones en pédiatrie. Paris: Médicine-Sciences, Flammarion, 1994: 105–10Google Scholar
  39. 39.
    Dagan R, Schlaeffer F, Einhorn M. Parenteral fluoroquinolones for the treatment of life-threatening infections not responding to other antibiotics. Infection 1990; 18: 45–6CrossRefGoogle Scholar
  40. 40.
    Linder N, Dagan R, Kuint J, et al. Ventriculitis caused by Klebsiellapneumoniae successfully treated with pefloxacin. Infection 1994; 22: 210–12PubMedCrossRefGoogle Scholar
  41. 41.
    Gilja OH, Halstensen A, Digranes A, et al. Use of single-dose ofloxacin to eradicate tonsilopharyngeal carriage of Neisseria meningitidis. Antimicrob Agent Chemother 1993; 37: 2024–6CrossRefGoogle Scholar
  42. 42.
    Dworzack DL, Sanders CC, Horowitz EA, et al. Evaluation of single-dose ciprofloxacin in the eradication of Neisseria meningitidis for nasopharyngeal carriers. Antimicrob Agent Chemother 1988; 32: 1740–1CrossRefGoogle Scholar
  43. 43.
    Hart CA, Cuevas LF, Kazembe P, et al. The use of ciprofloxacin to eradicate oropharyngeal carriage of Neisseria meningitidis: a preliminary analysis. Adv Antimicrob Antineopl Chemother 1992; 11-2: 167–71Google Scholar
  44. 44.
    Canada Communicable Disease Report 1994; 20-3: 17-27Google Scholar
  45. 45.
    Lang R, Goshen S, Raas-Rothchild A, et al. Oral ciprofloxacin in the management of chronic suppurative otitis media without cholesteatoma in children: preliminary experience in 21 children. Pediatr Infect Dis J 1992; 11: 925–9PubMedCrossRefGoogle Scholar
  46. 46.
    Lang R, Goshen S, Raas-Rothschild A, et al. Treatment of pediatric chronic suppurative otitis media by oral ciprofloxacin. A clinically effective and non-toxic therapeutic modality [abstract]. 5th International Symposium on New Quinolones: 1994 August 25–27: SingaporeGoogle Scholar
  47. 47.
    Hussey G, Kibel M, Parker N. Ciprofloxacin treatment of multiply drug-resistant extrapulmonary tuberculosis in a child. Pediatr Infect Dis J 1992; 11: 408–4PubMedCrossRefGoogle Scholar
  48. 48.
    Aujard Y, Bauman C, Bedu A, et al. Utilisation des quinolones en néonatologie. In: Aujard Y, Gendrel D, editors. Les quinolones en pédiatrie. Paris: Médecine-Sciences, Flammarion, 1994: 64–9Google Scholar
  49. 49.
    Lumbiganon P, Pengsaa K, Sookpranec T. Ciprofloxacin in neonates and its possible adverse effect on the teeth. Pediatr Infect Dis J 1991; 10: 619–20PubMedCrossRefGoogle Scholar
  50. 50.
    Friedland IR, Paris M, Ehrett S, et al. Evaluation of antimicrobial regimens for treatment of experimental penicillin and cephalosporin-resistant pneumococcal meningitis. Anti-microb Agents Chemother 1993; 37: 1630–6CrossRefGoogle Scholar
  51. 51.
    Piddock LJV. New fluoroquinolones and Gram-positive bacteria. Agent with good activity will soon be available. ASM News 1993; 59: 603–8Google Scholar
  52. 52.
    Magallanes M, Diskstra J, Fierer J. Liposome-incorporated ciprofloxacin in treatment of murine salmonellosis. Anti-microb Agents Chemother 1993; 37: 2293–7CrossRefGoogle Scholar
  53. 53.
    Shalit I. Immunological aspects of new quinolones. Eur J Clin Microbiol Inf Dis 1991; 10: 262–6CrossRefGoogle Scholar
  54. 54.
    Rubinstein E, Shalit I. Effects of the quinolones on the immune system. In: Hooper DC, Wolfson JS, editors. Quinolone antimicrobial agents. Washington D.C: American Society of Microbiology, 1993: 519–26Google Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Ron Dagan
    • 1
  1. 1.Pediatric Infectious Disease Unit, Soroka Medical Center and Faculty of Health SciencesBen-Gurion University of the NegevBeer-ShevaIsrael

Personalised recommendations